Skip to content

Effects of Packed Red Blood Cell Storage Duration on Pediatric Living Donor Liver Transplantation

Effects of Packed Red Blood Cell Storage Duration on Pediatric Living Donor Liver

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04413721
Enrollment
360
Registered
2020-06-04
Start date
2020-07-01
Completion date
2024-08-01
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transfusion Related Complication

Brief summary

The patients assigned to either short-storage leukoreduced RBCs group (stored for ≤ 14 days) or longer-term storage leukoreduced RBCs group(stored for ≥21 days).When the hemoglobin concentration fell below 7.0 g per deciliter, PRBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0/dL. The primary outcome : Death from all causes in1-year after randomization. Secondary outcomes included: Intraoperative blood transfusion, Postoperative blood transfusion, Postoperative inflammatory reaction, Mechanical ventilation time in the intensive care unit, Lengths of stay in the intensive care unit and the hospital were also recorded.

Interventions

PROCEDURERBC transfustion

When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Months to 36 Months
Healthy volunteers
No

Inclusion criteria

* Our study included pediatric patients (6 months\< the moon's age \<36 months) who will receive standard living-donor liver transplantation (LDLT) in Renji Hospital.

Exclusion criteria

* The exclu¬sion criteria of the study were a congenital sufferer from heart, lung, kidney, nervous system or blood disease,active Lung infection,a history of liver transplantation,Multivisceral transplantation , refused to participate the study.

Design outcomes

Primary

MeasureTime frameDescription
Mortality in in1-year after randomization1-year after randomization.Death from all causes in1-year after randomization.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026